Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Total Voting Rights

31st Mar 2015 12:47

RNS Number : 9892I
Vernalis PLC
31 March 2015
 

TOTAL VOTING RIGHTS

 

VERNALIS PLC (the "Company")

 

31 March 2015

 

Vernalis plc (LSE: VER) announces that for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 442,318,262 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

 

The total number of voting rights in the Company is therefore 442,318,262.

 

The above figure of 442,318,262 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

 

Enquiries:

 

Vernalis plc:

Ian Garland, Chief Executive Officer

+44 (0) 118 938 0015

David Mackney, Chief Financial Officer

 

Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8350

Dr Julian Feneley

Henry Fitzgerald-O'Connor

Pippa Underwood

 

Shore Capital (Joint Broker):

+44 (0) 20 7408 4090

Bidhi Bhoma

Toby Gibbs

 

Brunswick Group:

+44 (0) 20 7404 5959

Jon Coles

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

 

For further information about Vernalis, please visit www.vernalis.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRUAARRVSAOOAR

Related Shares:

Vernalis PLC
FTSE 100 Latest
Value8,809.74
Change53.53